Table 2.

Incidence of related adverse events per grade

Drug-related adverse eventsIncidence of related adverse events
Grade IGrade IIGrade IIIGrade IVUnknownTotal
General disorders and administration site conditions27/3215/324/322/3231/32
 Pyrexia16/3211/321/3220/32
 Chills15/326/3218/32
 Fatigue12/324/321/3214/32
 Edema, peripheral5/321/325/32
 Asthenia4/321/321/324/32
 Hyperhidrosis3/323/32
 Chest pain1/321/321/32
 Drug intolerance1/321/32
 Extravasation1/321/32
 Influenza-like illness1/321/32
 Edema1/321/32
 Pain1/321/32
Gastrointestinal disorders19/3212/321/3224/32
 Vomiting10/327/3214/32
 Nausea8/328/321/3214/32
 Diarrhea5/322/326/32
 Constipation3/323/32
 Abdominal pain1/321/322/32
 Dry mouth2/322/32
 Gingivitis1/321/32
 Oral dysesthesia1/321/32
 Stomatitis1/321/32
Skin and subcutaneous tissue disorders14/326/321/3219/32
 Rash6/323/328/32
 Pruritus6/323/327/32
 Erythema3/321/324/32
 Itching scar2/322/32
 Xeroderma2/321/322/32
 Alopecia1/321/32
 Dry skin1/321/321/32
 Urticaria1/321/32
Musculoskeletal and connective tissue disorders8/328/3214/32
 Arthralgia4/327/329/32
 Pain in extremities4/324/32
 Myalgia1/321/32
 Hypertonia1/321/32
 Joint range of motion decreased1/321/32
 Musculoskeletal pain1/321/32
 Trismus1/321/32
Vascular disorders7/325/324/321/3211/32
 Hypotension7/325/323/3211/32
 Embolism1/321/32
 Presyncope1/321/32
 Thrombosis1/321/32
Nervous system disorders9/322/3210/32
 Headache4/321/324/32
 Vertigo3/323/32
 Dizziness 2/322/32
 Dysesthesia 1/321/32
 Paresthesia1/321/32
 Tremor1/321/32
Blood and lymphatic system disorders3/325/324/322/328/32
 Leukopenia1/321/321/321/324/32
 Neutropenia3/323/324/32
 Anemia1/321/321/321/323/32
 Thrombocytopenia1/321/32
Metabolism and nutrition disorders4/323/327/32
 Anorexia4/324/32
 Decreased appetite1/321/32
 Dehydration1/321/32
 Hyperthyroidism1/321/32
Metabolic and laboratory disorders4/322/322/326/32
 Increased alanine aminotransferase2/322/32
 Increased blood bilirubin2/322/32
 Increased platelet count1/321/322/32
 Increased blood creatine1/321/32
 Increased body weight1/321/32
 Increased γ-glutamyltransferase1/321/32
Renal and urinary disorders5/326/32
 Oliguria2/322/32
 Proteinuria2/322/32
 Nocturia1/321/32
Respiratory, thoracic, and mediastinal disorders2/322/324/32
 Cough1/321/322/32
 Laryngitis1/321/32
 Rhinorrhea1/321/32
Infections and infestations1/321/322/32
 Candidiasis1/321/32
 Dental pulp disorder1/321/32
Cardiac disorders1/321/321/321/321/32
 Arrhythmia1/321/32
 Extrasystoles1/321/32
 Palpitations1/321/32
 Tachycardia1/321/32
Ear and labyrinth disorders (i.e., tinnitus)1/321/32
Eye disorders (i.e., vision blurred)1/321/32
Psychiatric disorders (i.e., depressed mood)1/321/32
Reproductive system and breast disorders (i.e., penile swelling)1/321/32

NOTE: The number of patients who experienced a certain side effect of a certain grade, over the total number of treated patients is reported in the table. Events which changed grade over time are listed as single events of the highest grade assumed.